Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

AI Agents Enter Regulated Workflows; Penn Medicine Starts a New Healthcare Shift – Copy

Compass Pathways has reported new six-month Phase III data showing that its psilocybin-based therapy, COMP360, continued to provide durable clinical benefits for patients with treatment-resistant depression. While the efficacy results attracted attention, the announcement also moves the therapy closer to
  • News
COMP360 Nears FDA Approval; Validation Requirements May Soon Change

AI Agents Enter Regulated Workflows; Penn Medicine Starts a New Healthcare Shift

Penn Medicine has integrated K Health’s AI-powered patient intake agents into its virtual primary care service, marking another step toward embedding AI agents into regulated clinical workflows. Rather than replacing clinicians, the system gathers patient information before appointments and delivers
  • News
AI Agents Enter Regulated Workflows; Penn Medicine Starts a New Healthcare Shift

Boston Is Losing Its Edge; Three Unexpected Cities Are Winning Pharma Investment

New pharmaceutical manufacturing investments are beginning to reshape the U.S. biotech landscape beyond traditional hubs like Boston and Cambridge. According to a report by Alexandra Pecci published on July 6, Lancaster County, Oklahoma City and Las Vegas are attracting major
  • News
Boston Is Losing Its Edge; Three Unexpected Cities Are Winning Pharma Investment

CMS Raises Outpatient Payments; 340B Cuts Could Rewrite Hospital Drug Economics

The Centers for Medicare & Medicaid Services (CMS) has released its proposed 2027 Hospital Outpatient Prospective Payment System rule, introducing a 2.4% outpatient payment increase while proposing significant reductions in the 340B Drug Pricing Program reimbursement and expanding site-neutral payment
  • News
CMS Raises Outpatient Payments; 340B Cuts Could Rewrite Hospital Drug Economics

Earlier Malignancy Signals Challenged Obefazimod; New Phase III Data Strengthens NDA Path

Abivax has reported new Phase III maintenance data showing that obefazimod maintained a favorable benefit-risk profile in adults with moderate to severe ulcerative colitis, despite safety concerns raised only weeks earlier. The updated findings strengthen the company's planned New Drug
  • News
Earlier Malignancy Signals Challenged Obefazimod; New Phase III Data Strengthens NDA Path

AstraZeneca’s $1.7B AI Kidney Deal Exposes Hidden Validation Risks; Inside CSPC Partnership Shift in Pharma R&D Strategy

AstraZeneca has entered a $1.7 billion kidney disease drug discovery partnership with China-based CSPC Pharmaceutical Group, expanding their ongoing collaboration into renal therapeutics using siRNA-based drug discovery and AI-driven molecular design systems. The agreement, announced on July 3, 2026, aims
  • News
AstraZeneca’s $1.7B AI Kidney Deal Exposes Hidden Validation Risks; Inside CSPC Partnership Shift in Pharma R&D Strategy

EMA Exposes Clinical Trial Blind Spot; Women’s Data Gaps Could Delay Drug Approvals in 2026

The European Medicines Agency (EMA) has launched a major initiative to address long-standing gaps in women’s health representation within clinical trials and regulatory evidence frameworks. Announced on 2 July 2026, the initiative focuses on improving sex-based data integration in drug
  • News
EMA Exposes Clinical Trial Blind Spot; Women’s Data Gaps Could Delay Drug Approvals in 2026

FDA Finds Gaps in Genzyme’s Data Integrity Program; Warning Letter Cites Discarded Review Records

The FDA has issued a warning letter to Sanofi’s Genzyme manufacturing facility in Waterford, Ireland, after identifying significant weaknesses in Data Integrity and quality management during an inspection. The agency found deficiencies in laboratory record reviews, traceability, and deviation handling
  • News
FDA Finds Gaps in Genzyme's Data Integrity Program; Warning Letter Cites Discarded Review Records

US Reshoring Looks Promising; GMP Validation Could Be the Real Bottleneck

New analysis suggests that pharmaceutical tariffs alone may not achieve the reshoring goals many policymakers expect. According to legal and industry experts in the United States, the economics of generic drug manufacturing, combined with GMP compliance costs and validation requirements,
  • News
US Reshoring Looks Promising; GMP Validation Could Be the Real Bottleneck

Roche Launches AXELIOS 1; Could This Transform Genome Sequencing?

Roche has unveiled AXELIOS 1 Sequencing Platform, its next-generation single-molecule sequencing system powered by Sequencing by Expansion (SBX) technology. The platform delivers same-day whole-genome sequencing while combining high accuracy, flexible throughput, and near real-time analysis. The launch reflects the growing
  • News
Roche Launches AXELIOS 1; Could This Transform Genome Sequencing?